FARMINGTON, Conn., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Immuron Limited: According to AAA research released this week, 48.7 million Americans are expected to travel within the U.S. this Thanksgiving. Many will unfortunately get sick, or experience intestinal discomfort, from the food they eat.
And, while most people associate improper sanitation of food and water during international travel with E. coli-based illnesses, last year’s largest ongoing E. coli outbreak was actually in the United States, and took place at several Chipotle restaurants. So it’s important to be prepared when you stop for a quick bite to eat as you travel for your holiday celebrations.
Travelan was developed by Australian bio-pharmaceutical company Immuron Limited to help protect your intestinal track against the 13 most common strains of E. coli*. Popular in its native Australia for the past 10 years, and in Canada for the past three years, Travelan is now available in the United States on CVS.com and in select CVS/pharmacy stores, on Amazon.com, at Passport Health clinics and other travel medical providers.
About Travelan:
- Travelan is a non-prescription dietary supplement uniquely formulated to be high in antibodies that can help support and maintain gastrointestinal and digestive function and health.
- Travelan’s active ingredient is Hyperimmune Bovine Colostrum Powder, which has been specifically engineered to be a rich source of antibodies that bind to Enterotoxigenic E. coli in the gastrointestinal tract, preventing them from attaching to the intestinal wall and thereby neutralizing their ability to cause diarrhea and its associated symptoms.
- Hyperimmune Colostrum was developed with Immuron’s Proprietary Technology to create high titers of antibodies to a range of E-Coli bacteria that is present in normal colostrum in only very small amounts.
About Immuron Limited:
Immuron Limited™ is a publicly listed Australian bio-pharmaceutical company (ASX:IMC) focused on oral immunotherapy using polyclonal antibody products. Immuron is a uniquely positioned company developing therapeutic products in NASH (fatty-liver disease), ASH (alcoholic fatty-liver disease) and other diseases mediated through gut dysbiosis.
Visit www.Immuron.com to learn more about the company or www.TravelanUSA.com to learn more about Travelan.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.